These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10163576)

  • 1. ACE inhibition in diabetic patients. Economic implications.
    Rodby RA; Lewis EJ
    Pharmacoeconomics; 1996 Oct; 10(4):315-20. PubMed ID: 10163576
    [No Abstract]   [Full Text] [Related]  

  • 2. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group.
    Rodby RA; Firth LM; Lewis EJ
    Diabetes Care; 1996 Oct; 19(10):1051-61. PubMed ID: 8886549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment.
    Parving HH
    Diabetologia; 1998 Jul; 41(7):745-59. PubMed ID: 9686914
    [No Abstract]   [Full Text] [Related]  

  • 4. ACE inhibitors as a shield against diabetic nephropathy.
    Materson BJ
    Arch Intern Med; 1996 Feb; 156(3):239-40. PubMed ID: 8572832
    [No Abstract]   [Full Text] [Related]  

  • 5. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients.
    Hendry BM; Viberti GC; Hummel S; Bagust A; Piercy J
    QJM; 1997 Apr; 90(4):277-82. PubMed ID: 9307762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure?
    Kiberd BA; Jindal KK
    Mayo Clin Proc; 1999 Jun; 74(6):559-64. PubMed ID: 10377929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of nephropathy and lipid disorders. Making progress while heeding Molière's warning.
    Bloomgarden ZT
    Diabetes Care; 1994 Aug; 17(8):946-8. PubMed ID: 7956651
    [No Abstract]   [Full Text] [Related]  

  • 8. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.
    Golan L; Birkmeyer JD; Welch HG
    Ann Intern Med; 1999 Nov; 131(9):660-7. PubMed ID: 10577328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy.
    Garattini L; Brunetti M; Salvioni F; Barosi M
    Pharmacoeconomics; 1997 Jul; 12(1):67-75. PubMed ID: 10169388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephropathy in patients with type 2 diabetes mellitus.
    Ritz E; Orth SR
    N Engl J Med; 1999 Oct; 341(15):1127-33. PubMed ID: 10511612
    [No Abstract]   [Full Text] [Related]  

  • 11. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy.
    Clark WF; Churchill DN; Forwell L; Macdonald G; Foster S
    CMAJ; 2000 Jan; 162(2):195-8. PubMed ID: 10674051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Going out to detect incipient diabetic nephropathy rather than waiting until it has supervened--a reversal in policy.
    Parving HH
    Nephrol Dial Transplant; 1996 Sep; 11(9):1728-9. PubMed ID: 8918612
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria.
    Mathiesen ER; Hommel E; Hansen HP; Smidt UM; Parving HH
    BMJ; 1999 Jul; 319(7201):24-5. PubMed ID: 10390455
    [No Abstract]   [Full Text] [Related]  

  • 14. A cost-effectiveness analysis of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy.
    Stafylas PC; Sarafidis PA; Grekas DM; Lasaridis AN
    J Clin Hypertens (Greenwich); 2007 Oct; 9(10):751-9. PubMed ID: 17917502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACE inhibitors and diabetic nephropathy.
    Molitch ME
    Diabetes Care; 1994 Jul; 17(7):756-60. PubMed ID: 7924789
    [No Abstract]   [Full Text] [Related]  

  • 16. Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation.
    Kiberd BA; Jindal KK
    Am J Kidney Dis; 1998 Jan; 31(1):49-54. PubMed ID: 9428451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACE inhibitors and renoprotection.
    Peterson K
    J Fam Pract; 1996 May; 42(5):453. PubMed ID: 8642355
    [No Abstract]   [Full Text] [Related]  

  • 18. [Diabetic nephropathy--manage now!].
    Ritz E
    Dtsch Med Wochenschr; 2010 Mar; 135(9):p8. PubMed ID: 20200822
    [No Abstract]   [Full Text] [Related]  

  • 19. Diabetic nephropathy and renal protective agents.
    Marchiando R; Elston MP
    S D J Med; 1999 Oct; 52(10):385-6. PubMed ID: 10546516
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands--a Markov model.
    Adarkwah CC; Gandjour A; Akkerman M; Evers SM
    PLoS One; 2011; 6(10):e26139. PubMed ID: 22022539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.